Pieris Pharmaceuticals, Inc. has entered into an Agreement and Plan of Merger with Palvella Therapeutics, Inc. for a tax-free reorganization and non-taxable exchange of shares, with pre-Merger Palvella stockholders expected to own approximately 82% of the combined company on a pro forma basis.